Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T-cell Therapy for Pediatric CD19-positive B-cell Acute Lymphoblastic Leukemia Indicated for HSCT
KCT0009199Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2024
- Countries
- 1
- Sponsor
- Child Cancer & Rare Disease Project
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Drugs
- UCD19 CAR-T
- Conditions
- B cell acute lymphoblastic leukemia (B-ALL)
01
Overview
Phase 2, single-arm trial of UCD19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Child Cancer & Rare Disease Project. Started Jan 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedSingle group
CD19 CAR T-cell therapy
Pediatric patients with CD19-positive B-cell acute lymphoblastic leukemia indicated for HSCT receive CD19 CAR T-cell therapy in a single-group Phase 2 design.
03
Who it enrols
Pediatric patients with CD19-positive B-cell acute lymphoblastic leukemia who are indicated for hematopoietic stem cell transplantation.
Beyond the preview
Go deeper on KCT0009199.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009199.